Psychedelic Stocks Archives - Page 12 of 61

MondayFeb 05, 2024 10:30 am

Canadian Companies Set to Reap Big from Psychedelics Exports to Australia

Several Canadian biotechnology companies are poised to make a killing in the Australian market after the county’s Therapeutic Goods Administration (TGA) allowed psychiatrists to prescribe MDMA and psilocybin in 2023. The TGA regulates therapeutic goods such as medical devices and prescription drugs in Australia. It approved the prescription of psilocybin, the main psychoactive agent in magic mushrooms, and MDMA by changing their classification in Australia’s Poisons Scheme. The TGA’s changes to the Poisons Scheme mean that the two psychedelics are considered Schedule 8 Controlled Drugs for specific uses. However, psilocybin and MDMA will remain in Schedule 9 (Prohibited Substances), which…

FridayFeb 02, 2024 1:21 pm

Hawaii Task Force Files Bill Creating Program for Medicinal Psilocybin Use

Hawaii recently introduced a new measure that would establish legal protections for psilocybin’s therapeutic use. Under SB 3019, eligible patients would be allowed to possess the psychedelic and receive it under the care of a trained facilitator. The legislation, which was sponsored by Senator Chris Lee, was introduced by a task force formed in 2023 to look into breakthrough therapies. While the measure won’t legalize the psychedelic, it would defend eligible patients and their caregivers from state laws against psilocybin. Under SB 3019, mental health professionals would be allowed to recommend therapeutic psilocybin for individuals who met the stipulated eligibility…

ThursdayFeb 01, 2024 2:30 pm

Why Psychedelics Could Encounter Regulatory Roadblocks at State, Federal Levels

A recent influx in psychedelic-related research has revealed that some classic psychedelic drugs have the potential to offer long-term relief against several mental disorders. The expanding scientific literature states that psychedelics such as LSD, psilocybin (magic mushrooms) and ayahuasca may be able to treat debilitating mental disorders, including treatment-resistant depression, eating disorders and post-traumatic stress disorder (PTSD). As a result, there have been growing calls to legalize therapeutic psychedelic use to provide mental-health patients with access to safer and more effective alternative treatments. However, regulatory roadblocks at the state and federal levels could frustrate efforts to legalize psychedelics for therapeutic…

WednesdayJan 31, 2024 12:38 pm

Mouse Study Shows Microdoses of Psilocybin Can Combat Anhedonia

Researchers from the University of Southern Denmark have discovered that microdoses of psilocybin, the main psychoactive agent in mushrooms, may be able to alleviate anhedonia. The study used a mouse study to discover that regular small doses of the psychedelic may offer therapeutic benefits against stress-induced anhedonia, a condition that strips individuals of their ability to feel pleasure, and compulsive behavior. Furthermore, psilocybin exhibited therapeutic effectiveness in mice with anhedonia and compulsive behaviors without inducing side effects such as schizophrenia-like symptoms and anxiety. The University of Southern Denmark University team published its findings in the “Molecular Psychiatry” journal. Most of…

MondayJan 29, 2024 1:21 pm

EU Finances First Psychedelics Research on Incurable Illnesses

The European Union (EU) is funding research into psychedelic-based therapies for patients with incurable diseases. Researchers will use EU funding to determine if psychedelic drugs such as psilocybin can help alleviate psychologic distress in palliative-care patients. While palliative and end-of-life care are designed to relieve physical symptoms and make patients as comfortable as possible, there aren’t a lot of protocols to alleviate the psychological distress that often accompanies incurable illnesses. Psychedelics have exhibited significant potential as mental-health treatments in several initial studies and have shown that they can treat significant mental distress in conditions such as depression and post-traumatic stress…

FridayJan 26, 2024 12:43 pm

Researchers Gain New Insights into Reports of Mystical Psychedelic Experiences

Researchers from the University of Split’s Medical School’s Department of Medical Humanities recently used computerized linguistic tools to gain insight into online reports of mystical psychedelic experiences. The scientists found that intense psychedelic experiences tend to be accompanied by an increase in negative emotions and mystical language in users. While prior psychedelic-related research typically occurs in clinical settings and leverages structured questionnaires to collect information on mystical psychedelic experiences, the experiences are often limited in depth and nuance. Instead of using questionnaires, the research team analyzed self-reported experiences from actual psychedelic users to obtain new insight into the users’ experiences…

ThursdayJan 25, 2024 3:15 pm

First Responders, Medical Professionals Implore Nevada Legislators to Reform Psychedelics Laws

Numerous medical professionals and first responders have urged Nevada lawmakers to reform psychedelic laws and allow the use of psychedelics in mental-health treatment. The professionals spoke to a panel of state legislators from the state’s Joint Interim Standing Committee on the Judiciary. Psychedelics have exhibited significant potential as alternative mental-health treatments in recent years, especially against mental disorders such as post-traumatic stress disorder (PTSD) and depression, which often do not respond to conventional treatments. Due to the sometimes traumatic nature of their careers, veterans and first responders often develop conditions such as PTSD and depression after several years on the…

WednesdayJan 24, 2024 3:04 pm

Nevada Lawmakers Receive Testimonies on Benefits, Concerns Regarding Psychedelics Legalization

A joint legislative committee in the state of Nevada recently heard testimonies on the therapeutic potential of psychedelics. The presentations centered on the impact and science of psychedelic-assisted therapy, with representatives of the Joint Interim Standing Committee focusing on the judiciary also discussing its concerns around psychedelic legalization. The panel was introduced by Senator Rochelle Nguyen, who stated that the presentation’s purpose was to afford the committee an overview of psychedelics. Nguyen sponsored a measure that would establish a state working group to conduct research on psychedelics and come up with plans to permit regulated therapeutic access to the drugs.…

TuesdayJan 23, 2024 2:28 pm

AlphaFold Uncovers Thousands of Potential Psychedelic Proteins

Researchers recently used an artificial intelligence (AI) tool developed by London-based artificial intelligence research laboratory Deepmind Technologies Limited to identify thousands of potential psychedelic proteins. Called AlphaFold, the artificial intelligence protein-structure prediction tool found hundreds of thousands of new potential psychedelic molecules that could be instrumental in the development of novel antidepressants. The research is a testament to AlphaFold’s ability to easily provide predictions that have applications in everything from experimentally derived protein structure to drug discovery in a fraction of the time such endeavors would have previously taken. AlphaFold’s public database currently has structure predictions for almost every known…

MondayJan 22, 2024 2:53 pm

New Study Provides Possible Explanation for Antidepression Effects of Psychedelic

A recent study has suggested that psychedelics may deliver their antidepressive effects by “shaking up” the brain networks responsible for regulating emotion. Major advances in psychedelic research have revealed that classic psychedelics have the potential to treat various mental disorders with barely any negative side effects. Researchers have found that psychedelics such as LSD, MDMA and psilocybin can offer long-term relief against a variety of conditions, including anxiety, depression and post-traumatic stress disorder at relatively low doses. Most of this research is still in its infancy, but the findings are so encouraging that companies are investing tens of millions of…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Psychedelic Stocks